第十一批国采，医疗机构可自主选择厂牌

Core Viewpoint - The eleventh batch of national drug centralized procurement is progressing steadily, with new systematic requirements for reporting procurement demand from medical institutions, emphasizing "reasonableness" and "sufficiency" as key indicators for review [1][2]. Group 1: Reporting Mechanism - The new notification allows medical institutions to independently select the specifications or brands of drugs for reporting, addressing previous concerns about the inability to use clinically needed brands [3]. - The notification enhances transparency by being directly published by the procurement office, which is expected to increase the initiative of medical institutions in the procurement process [2]. Group 2: Data Integrity and Responsibility - Medical institutions are required to submit procurement demand based on a comprehensive assessment of clinical needs, procurement records, and usage trends, with a stipulation that if reported quantities are below 80% of the average procurement volume for 2023-2024, explanations must be provided [2]. - The new rules aim to improve the reliability of reported data, addressing past issues of "low reporting and high consumption" that distorted the procurement process [2]. Group 3: Regulatory Enhancements - The notification mandates local medical insurance departments to conduct logical audits of reported data, focusing on service capacity and historical procurement discrepancies [4]. - The shift in policy design transforms the reporting process from a mere "form-filling action" to a "commitment of responsibility," indicating a substantial change in management approach from the insurance side [4]. Group 4: Future Implications - The emphasis on "demand-driven quantity" is seen as a significant complement to the "quantity-for-price" mechanism, with future procurement data's effectiveness and deliverability becoming critical indicators for the stability of the system [4].